2nd Annual Oligonucleotides for CNS Summit

With Biogen investing millions in Ionis' efforts to weaponize ASOs against SMA, Stoke Therapeutics collaborating with Acadia Pharmaceuticals to supercharge the development of RNA-Based treatments for genetic neurodevelopmental diseases and the global oligonucleotide therapeutics market set to experience unprecedented growth, there’s never been a more opportune moment for biopharma to expand their oligonucleotide pipelines into the untapped potential of the CNS.

Dedicated to providing you with the insights you need to create clinically defining oligonucleotide therapeutics, the 2nd Oligonucleotides for CNS Summit will unite a multinational faculty of experts from Eli Lilly, Roche, Biogen, Alnylam, Servier, Stoke Therapeutics and more to divulge the critical insights you need to accelerate your oligonucleotide therapeutic development against Alzheimer’s, Huntington’s, Glioblastoma and more!

From learning how to manipulate oligonucleotide chemistry to maximize therapeutic potency to more effectively collaborating with CROs/CMOs to manufacture therapies in line with regulatory standards and exploring antibodies, small Molecules & nanoparticles for movement across the blood brain barrier, this focused industry forum will give you the chance to gain back-to-back insights on the science propelling oligonucleotide therapeutics forward in 2022. 

As industry turn their heads towards the CNS in a bid to capitalize on its strategic opportunity,  join 150+ ASO and RNA-Based therapeutic experts this June at this unique forum for a dynamic mix of formal presentations, audience discussions, panel discussions and organized networking and leave with the expertise your team needs to optimize your oligonucleotides approach in the CNS this year.

Tickets https://go.evvnt.com/1054624-2?pid=5248
Brochure https://go.evvnt.com/1054624-3?pid=5248

Speakers: Alfica Sehgal, Senior Vice President & Head of Discovery, Translation Discovery, CAMP4 Therapeutics, Alicia Secor, President & Chief Executive Officer, Atalanta Therapeutics, Angela Wagner, Principal Scientist, Merck, Anna M. Krichevsky, Ph.D. Associate Professor of Neurology, Harvard Medical School, Dan Williams, Chief Executive Officer, Synaptix Bio, David Corey, Professor, UT Southwestern Medical Center, Dee Datta, Chief Executive Officer, Switch Therapeutics, Erich Koller, Senior Principal Scientist, Roche, Firoz Antia, Senior Director & Head of Oligonucleotide Process Development, Biogen, George Tachas, Director of Drug Discovery & Patents, Antisense Therapeutics, Graham Dempsey, Chief Scientific Officer, Q State Bio, Hagen Cramer, Chief Production Officer, QurAlis, Irina Antonijevic, Chief Medical Officer & Head of R&D, Triplet Therapeutics, Julia Alterman, Assistant Professor, RNA Therapeutics Institute, UMass Chan Medical School, Justin Fallon, Scientific CoFounder, Bolden Therapeutics, Ken Yamada, Assistant Professor, University of Massachusetts Medical School, Lisa Shafer, Chief Scientific Officer, Cerebral Therapeutics, Mano Manoharan, Senior Vice President, Innovation Chemistry, Alnylam, Meena Stoke, Vice President of Bioanalytical, DMPK & Biomarker Development, Stoke Therapeutics, Miriam Bujny, Chief Development Officer, Sapreme Technologies, Morgan Carlson, Senior Director of Biology, Regulus Therapeutics, Murali Gopalakrishnan, Global Head, Neuroscience Search & Evaluation, AbbVie, Peter Wuelfing, Executive Director, Merck, Raj Pandey, Vice President & Head of Chemistry, Cargene Therapeutics, Riazul Alam, Research Scientist, Eli Lilly & Company, Sharon Manashirov, Head of Science, miCure Therapeutics, Si-ping Han, Chief Technology Officer, Switch Therapeutics, Smitha Jagadish, Director of Neuroscience & Pain New Modalities, Grunenthal, Susan Rosenbaum, Founder, Chairman & CEO, Lauren Sciences, Thierry Dorval, Head of Data Sciences & Management, Servier

Sesh by The Boston Calendar | Advertise Terms | Privacy Policy | About